关于微小RNA-155在癌症治疗中可能作用的系统综述。
完整摘要 · 中文译文
背景：microRNA-155（miR-155）过表达与癌症发生、转移及可能的耐药性相关。本系统综述分析了现有文献中关于接受治疗癌症患者miR-155表达的证据。 方法：于2019年1月至2024年12月在数据库和搜索引擎（ProQuest、PubMed和Google Scholar）中进行了全面的文献检索，以识别癌症治疗中miR-155表达的临床证据。为评估miR-155表达与临床结局的关系，本系统综述纳入15种癌症。遵循PRISMA 2020指南，三名独立评价者根据预定义的纳入标准进行文献筛选、数据提取和评估，第四名评价者对评估结果进行核实并解决分歧。 结果：在分析的15种癌症中，共识别出19项符合条件的研究，涵盖8种癌症，并纳入本综述，即乳腺癌、非小细胞肺癌、儿童急性淋巴细胞白血病、皮肤黑色素瘤、非肌层浸润性膀胱癌、甲状腺乳头状癌、胰腺导管腺癌和弥漫性大B细胞淋巴瘤。对这19项研究的筛选和评估显示，miR-155表达因癌症类型、治疗策略和患者样本类型而异。虽然大多数研究将miR-155过表达与治疗耐药相关联，但少数研究报道了miR-155表达升高与治疗敏感性增强之间的关联。本研究的局限性在于，对研究的检索 癌症患者中miR-155表达与治疗结局相关的报告仅限于三个数据库和5年时间范围。 结论：总体而言，本研究结果表明，miR-155的预后和预测意义值得进一步评估。 系统综述注册：PROSPERO ID，CRD42025632573。
完整摘要 · 英文原文
BACKGROUND: Overexpression of microRNA-155 (miR-155) has been associated with cancer development, metastasis, and possible drug resistance. This systematic review analyzed the evidence from the existing literature on miR-155 expression in cancer patients undergoing treatment. METHODS: A thorough literature search was conducted in databases and search engines (ProQuest, PubMed, and Google Scholar) from January 2019 to December 2024 to identify clinical evidence on miR-155 expression in cancer treatments. To assess miR-155 expression in relation to clinical outcomes, we included 15 cancers in this systematic review. Following the PRISMA 2020 guidelines, three independent reviewers selected, extracted, and assessed the data against the predefined inclusion criteria, and a fourth reviewer verified the assessments and resolved discrepancies. RESULTS: Of the 15 cancers analyzed, 19 eligible studies covering eight cancers were identified and included in the review, namely breast cancer, non-small cell lung cancer, pediatric acute lymphoblastic leukemia, cutaneous melanoma, non-muscle-invasive bladder cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma, and diffuse large B-cell lymphoma. Screening and evaluation of these 19 studies showed that miR-155 expression varied by cancer type, treatment strategy, and patient sample type. While most studies associated miR-155 overexpression with treatment resistance, a few reported an association between elevated miR-155 expression and enhanced treatment sensitivity. A limitation of this study is that the search for studies reporting miR-155 expression in relation to therapeutic outcomes in patients with cancer was restricted to three databases and a 5-year timeframe. CONCLUSION: Overall, the results of this study indicate that the prognostic and predictive significance of miR-155 warrants further evaluation. SYSTEMATIC REVIEW REGISTRATION: PROSPERO ID, CRD42025632573.